147 related articles for article (PubMed ID: 31479430)
1. Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice.
Klein AF; Varela MA; Arandel L; Holland A; Naouar N; Arzumanov A; Seoane D; Revillod L; Bassez G; Ferry A; Jauvin D; Gourdon G; Puymirat J; Gait MJ; Furling D; Wood MJ
J Clin Invest; 2019 Nov; 129(11):4739-4744. PubMed ID: 31479430
[TBL] [Abstract][Full Text] [Related]
2. Splicing biomarkers of disease severity in myotonic dystrophy.
Nakamori M; Sobczak K; Puwanant A; Welle S; Eichinger K; Pandya S; Dekdebrun J; Heatwole CR; McDermott MP; Chen T; Cline M; Tawil R; Osborne RJ; Wheeler TM; Swanson MS; Moxley RT; Thornton CA
Ann Neurol; 2013 Dec; 74(6):862-72. PubMed ID: 23929620
[TBL] [Abstract][Full Text] [Related]
3. Efficient systemic CNS delivery of a therapeutic antisense oligonucleotide with a blood-brain barrier-penetrating ApoE-derived peptide.
Yeoh YQ; Amin A; Cuic B; Tomas D; Turner BJ; Shabanpoor F
Biomed Pharmacother; 2024 Jun; 175():116737. PubMed ID: 38749176
[TBL] [Abstract][Full Text] [Related]
4. CaMKIIβ deregulation contributes to neuromuscular junction destabilization in Myotonic Dystrophy type I.
Falcetta D; Quirim S; Cocchiararo I; Chabry F; Théodore M; Stiefvater A; Lin S; Tintignac L; Ivanek R; Kinter J; Rüegg MA; Sinnreich M; Castets P
Skelet Muscle; 2024 May; 14(1):11. PubMed ID: 38769542
[TBL] [Abstract][Full Text] [Related]
5. Immortalized human myotonic dystrophy type 1 muscle cell lines to address patient heterogeneity.
Núñez-Manchón J; Capó J; Martínez-Piñeiro A; Juanola E; Pesovic J; Mosqueira-Martín L; González-Imaz K; Maestre-Mora P; Odria R; Savic-Pavicevic D; Vallejo-Illarramendi A; Mamchaoui K; Bigot A; Mouly V; Suelves M; Nogales-Gadea G
iScience; 2024 Jun; 27(6):109930. PubMed ID: 38832025
[TBL] [Abstract][Full Text] [Related]
6. RNA therapeutics: beyond RNA interference and antisense oligonucleotides.
Kole R; Krainer AR; Altman S
Nat Rev Drug Discov; 2012 Jan; 11(2):125-40. PubMed ID: 22262036
[TBL] [Abstract][Full Text] [Related]
7. Perfluoroaryl Bicyclic Cell-Penetrating Peptides for Delivery of Antisense Oligonucleotides.
Wolfe JM; Fadzen CM; Holden RL; Yao M; Hanson GJ; Pentelute BL
Angew Chem Int Ed Engl; 2018 Apr; 57(17):4756-4759. PubMed ID: 29479836
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of oleic acid supplementation in myotonic dystrophy muscle cell models.
Moreno N; Sabater-Arcis M; Sevilla T; Alonso MP; Ohana J; Bargiela A; Artero R
Biol Res; 2024 May; 57(1):29. PubMed ID: 38760841
[TBL] [Abstract][Full Text] [Related]
9. Machine Learning To Predict Cell-Penetrating Peptides for Antisense Delivery.
Wolfe JM; Fadzen CM; Choo ZN; Holden RL; Yao M; Hanson GJ; Pentelute BL
ACS Cent Sci; 2018 Apr; 4(4):512-520. PubMed ID: 29721534
[TBL] [Abstract][Full Text] [Related]
10. The sustained expression of Cas9 targeting toxic RNAs reverses disease phenotypes in mouse models of myotonic dystrophy type 1.
Batra R; Nelles DA; Roth DM; Krach F; Nutter CA; Tadokoro T; Thomas JD; Sznajder ŁJ; Blue SM; Gutierrez HL; Liu P; Aigner S; Platoshyn O; Miyanohara A; Marsala M; Swanson MS; Yeo GW
Nat Biomed Eng; 2021 Feb; 5(2):157-168. PubMed ID: 32929188
[TBL] [Abstract][Full Text] [Related]
11. The Dimeric Form of 1,3-Diaminoisoquinoline Derivative Rescued the Mis-splicing of Atp2a1 and Clcn1 Genes in Myotonic Dystrophy Type 1 Mouse Model.
Matsumoto J; Nakamori M; Okamoto T; Murata A; Dohno C; Nakatani K
Chemistry; 2020 Nov; 26(63):14305-14309. PubMed ID: 32449537
[TBL] [Abstract][Full Text] [Related]
12. Advances in oligonucleotide drug delivery.
Roberts TC; Langer R; Wood MJA
Nat Rev Drug Discov; 2020 Oct; 19(10):673-694. PubMed ID: 32782413
[TBL] [Abstract][Full Text] [Related]
13. Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3'UTR RNA.
Yadava RS; Yu Q; Mandal M; Rigo F; Bennett CF; Mahadevan MS
Hum Mol Genet; 2020 Jun; 29(9):1440-1453. PubMed ID: 32242217
[TBL] [Abstract][Full Text] [Related]
14. Increased Muscleblind levels by chloroquine treatment improve myotonic dystrophy type 1 phenotypes in in vitro and in vivo models.
Bargiela A; Sabater-Arcis M; Espinosa-Espinosa J; Zulaica M; Lopez de Munain A; Artero R
Proc Natl Acad Sci U S A; 2019 Dec; 116(50):25203-25213. PubMed ID: 31754023
[TBL] [Abstract][Full Text] [Related]
15. AAV9-DOK7 gene therapy reduces disease severity in Smn
Kaifer KA; Villalón E; Smith CE; Simon ME; Marquez J; Hopkins AE; Morcos TI; Lorson CL
Biochem Biophys Res Commun; 2020 Sep; 530(1):107-114. PubMed ID: 32828271
[TBL] [Abstract][Full Text] [Related]
16. AAV-Mediated CRISPR/Cas9 Gene Editing in Murine Phenylketonuria.
Richards DY; Winn SR; Dudley S; Nygaard S; Mighell TL; Grompe M; Harding CO
Mol Ther Methods Clin Dev; 2020 Jun; 17():234-245. PubMed ID: 31970201
[TBL] [Abstract][Full Text] [Related]
17. A mouse model for the cystic fibrosis delta F508 mutation.
van Doorninck JH; French PJ; Verbeek E; Peters RH; Morreau H; Bijman J; Scholte BJ
EMBO J; 1995 Sep; 14(18):4403-11. PubMed ID: 7556083
[TBL] [Abstract][Full Text] [Related]
18. The hallmarks of myotonic dystrophy type 1 muscle dysfunction.
Ozimski LL; Sabater-Arcis M; Bargiela A; Artero R
Biol Rev Camb Philos Soc; 2021 Apr; 96(2):716-730. PubMed ID: 33269537
[TBL] [Abstract][Full Text] [Related]
19. AON-induced splice-switching and DMPK pre-mRNA degradation as potential therapeutic approaches for Myotonic Dystrophy type 1.
Stepniak-Konieczna E; Konieczny P; Cywoniuk P; Dluzewska J; Sobczak K
Nucleic Acids Res; 2020 Mar; 48(5):2531-2543. PubMed ID: 31965181
[TBL] [Abstract][Full Text] [Related]
20. Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.
Marsh S; Hanson B; Wood MJA; Varela MA; Roberts TC
Mol Ther; 2020 Dec; 28(12):2527-2539. PubMed ID: 33171139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
